104395-86-0 Usage
Description
1-(5-Methyl-2-pyridinyl)piperazine is a piperazine analog that selectively targets the D4 receptor, which is crucial in central nervous system (CNS) pathologies. 1-(5-Methyl-2-pyridinyl)piperazine has the potential to be a significant pharmaceutical candidate due to its receptor specificity and implications in various CNS-related conditions.
Uses
Used in Pharmaceutical Industry:
1-(5-Methyl-2-pyridinyl)piperazine is used as a therapeutic agent for targeting the D4 receptor, which is associated with various central nervous system (CNS) pathologies. Its selective action on the D4 receptor makes it a promising candidate for the development of drugs aimed at treating CNS-related disorders.
Used in Research and Development:
1-(5-Methyl-2-pyridinyl)piperazine is used as a research tool in the study of the D4 receptor's role in CNS pathologies. 1-(5-Methyl-2-pyridinyl)piperazine can help researchers better understand the receptor's function and its potential as a target for therapeutic intervention in various neurological and psychiatric conditions.
Used in Drug Design and Development:
1-(5-Methyl-2-pyridinyl)piperazine serves as a lead compound in the design and development of new drugs targeting the D4 receptor. Its selective interaction with the receptor can guide the development of more effective and targeted treatments for CNS-related disorders, potentially leading to improved patient outcomes and quality of life.
Check Digit Verification of cas no
The CAS Registry Mumber 104395-86-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,4,3,9 and 5 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 104395-86:
(8*1)+(7*0)+(6*4)+(5*3)+(4*9)+(3*5)+(2*8)+(1*6)=120
120 % 10 = 0
So 104395-86-0 is a valid CAS Registry Number.
InChI:InChI=1/C10H15N3/c1-9-2-3-10(12-8-9)13-6-4-11-5-7-13/h2-3,8,11H,4-7H2,1H3
104395-86-0Relevant articles and documents
OGA INHIBITOR COMPOUNDS
-
Page/Page column 61, (2021/06/26)
The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.
SULFONIC ACID SALTS OF HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES
-
, (2014/10/29)
The invention relates to sulfonic acid salts of heterocyclylamide-substituted imidazoles, and to solvates and hydrates thereof, to the use thereof for treating and/or preventing diseases, and to use thereof for producing drugs for treating and/or preventi
HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES
-
Page/Page column 33, (2008/06/13)
The invention relates to heterocyclylamide-substituted imidazoles and methods for the production of the same, to the use thereof for the treatment and/or prophylaxis of diseases, to the use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases, and especially to the use thereof as antiviral agents, especially against cytomegaloviruses.
